Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial [CNBC]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: CNBC
The drugmaker is betting big on the treatment, retatrutide, as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. Dubbed the “triple G” drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. In this article The Eli Lilly logo appears on the company's office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly on Thursday said its next-generation obesity drug delivered strong weight loss and reduced knee arthritis pain in a late-stage study, clearing the first of several upcoming trials on the weekly injection. The highest dose of the drug helped patients with obesity and a type of knee arthritis lose an average of 23.7% of their body weight at 68 weeks, when analyzing all participants, including those who discontinued treatment. When evaluating only patients who stayed on the drug – essentially th
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Why Eli Lilly (LLY) Stock Is Trading Up Today [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..MarketBeat
- Eli Lilly and Company (NYSE:LLY) had its price target lowered by analysts at Bank of America Corporation from $1,286.00 to $1,268.00. They now have a "buy" rating on the stock.MarketBeat
- Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade) [Seeking Alpha]Seeking Alpha
- Eli Lilly and Company (NYSE:LLY) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $951.00 to $1,145.00. They now have a "buy" rating on the stock.MarketBeat
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/8/25 - Form 3
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- LLY's page on the SEC website